Company: TYRA
Filing Date: 2025-05-08
Form Type: S-3
Source: 0001193125-25-116008
Chunk: 52

Company: Tyra Biosciences, Inc.
Filing Date: 2025-05-08
Form: S-3
Chunk 52
---
 to the extent of the difference between the price per share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering. Our net tangible book value of our common stock as of March 31, 2025 was approximately $323.5 million, or approximately $6.09 per share of common stock based upon 53,089,957 shares outstanding as of such date. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of shares outstanding as of March 31, 2025. After giving effect to the sale of our common stock in the aggregate amount of $150.0 million at an assumed offering price of $10.00 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on May 6, 2025, and after deducting estimated offering commissions and estimated aggregate offering expenses payable by us, our net tangible book value as of March 31, 2025 would have been approximately $468.8 million, or $6.88 per share of common stock. This represents an immediate increase in net tangible book value of $0.79 per share to our existing stockholders and an immediate dilution in net tangible book value of $3.12 per share to new investors in this offering at the assumed public offering price. The following table illustrates this calculation on a per share basis:

| Assumed public offering price per share                                                       |     |   |      |     | $ | 10.00 |
| Net tangible book value per share as of March 31, 2025                                        |     | $ | 6.09 |     |   |       |
| Increase in net tangible book value per share attributable to the offering                    |     | $ | 0.79 |     |   |       |
| As adjusted net tangible book value per share as of March 31, 2025 after giving effect to the 
 offering                                                                                      |     |   |      |     | $ |  6.88 |
| Dilution in net tangible book value per share to new investors in this offering               |     |   |      |     | $ |  3.12 |

The number of shares of our common stock to be outstanding immediately after this offering is based on 53,089,957 shares of our common stock outstanding as of March 31, 2025. The number of shares outstanding as of March 31,